Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$1.95 USD
-0.03 (-1.52%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $1.93 -0.02 (-1.03%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Syros Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 140 | 202 | 130 | 174 | 92 |
Receivables | 0 | 0 | 0 | 0 | 20 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 9 | 6 | 5 | 3 |
Total Current Assets | 145 | 211 | 137 | 179 | 115 |
Net Property & Equipment | 7 | 11 | 13 | 14 | 15 |
Investments & Advances | 0 | 0 | 13 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 8 | 6 | 5 | 4 |
Total Assets | 168 | 244 | 183 | 213 | 150 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 12 | 6 | 4 | 4 | 6 |
Current Portion Long-Term Debt | 7 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 16 | 18 | 16 | 11 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 4 | 10 | 12 | 6 |
Total Current Liabilities | 37 | 31 | 32 | 29 | 24 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 10 | 23 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 35 | 41 | 40 | 40 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 1 |
Other Non-Current Liabilities | 62 | 24 | 3 | 20 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 152 | 117 | 98 | 123 | 71 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 739 | 686 | 549 | 468 | 372 |
Retained Earnings | -723 | -558 | -464 | -377 | -293 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 17 | 128 | 85 | 91 | 79 |
Total Liabilities & Shareholder's Equity | 168 | 244 | 183 | 213 | 150 |
Total Common Equity | 17 | 128 | 85 | 91 | 79 |
Shares Outstanding | 21.00 | 20.20 | 6.10 | 5.60 | 4.20 |
Book Value Per Share | 0.79 | 6.32 | 13.97 | 16.17 | 18.85 |
Fiscal Year End for Syros Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 79 | 108 | 140 | 112 | 144 |
Receivables | 0 | 0 | 0 | 2 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 4 | 5 | 9 | 7 |
Total Current Assets | 85 | 112 | 145 | 123 | 153 |
Net Property & Equipment | 7 | 7 | 7 | 8 | 10 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 4 | 4 | 5 | 5 |
Total Assets | 107 | 135 | 168 | 148 | 181 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 11 | 12 | 3 | 7 |
Current Portion Long-Term Debt | 0 | 12 | 7 | 2 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 15 | 12 | 16 | 21 | 17 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 2 |
Total Current Liabilities | 25 | 37 | 37 | 28 | 28 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 41 | 30 | 35 | 39 | 41 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 30 | 62 | 25 | 19 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 113 | 120 | 152 | 111 | 108 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 743 | 742 | 739 | 695 | 691 |
Retained Earnings | -750 | -727 | -723 | -658 | -618 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -6 | 15 | 17 | 36 | 73 |
Total Liabilities & Shareholder's Equity | 107 | 135 | 168 | 148 | 181 |
Total Common Equity | -6 | 15 | 17 | 36 | 73 |
Shares Outstanding | 26.80 | 26.70 | 21.00 | 20.70 | 20.60 |
Book Value Per Share | -0.24 | 0.56 | 0.79 | 1.75 | 3.56 |